Nykode Therapeutics to Showcase APC-Targeted DNA Vaccine Platform at 3rd Annual Personalized Cancer Vaccine Summit

On November 19, 2026 Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of cancer vaccines, reported that Chief Executive Officer, Michael Engsig, and Chief Scientific Officer and Co-founder, Agnete Fredriksen, will participate in the 3rd Annual Personalized Cancer Vaccine Summit, taking place December 1–3, 2026 in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nykode’s leadership will contribute to three sessions during the summit, sharing the company’s perspectives on the development, manufacturing, and clinical translation of personalized cancer vaccines.

"As interest in the field of individualized neoantigen cancer vaccines continues to grow, attention is increasingly turning to how these treatments can be delivered to patients at scale," said Agnete Fredriksen, Chief Scientific Officer and Co-founder of Nykode Therapeutics. "We believe our APCtargeted DNA platform offers a differentiated approach, supported by encouraging clinical immunogenicity data and an established manufacturing process. We look forward to contributing to discussions on the opportunities and challenges shaping the future of personalized cancer vaccines."

Nykode’s work in personalized cancer vaccines is being advanced through VB10.NEO, its wholly owned, DNA-based individualized neoantigen therapy (INT). Built on Nykode’s proprietary antigenpresenting cell (APC)-targeting technology and NeoSELECT, its AI-driven neoantigen selection engine, VB10.NEO is designed to deliver selected antigens to APCs to generate broad, potent, and long-lasting antigen-specific immune responses.

The company has established an end-to-end manufacturing process for VB10.NEO, achieving 100% manufacturing success across two clinical trials. Further optimization of the manufacturing process reduces the current turnaround-time from biopsy to product release to less than six weeks with a clear path to further reductions by additional consolidation under "one roof". Its plasmid DNA-based platform also offers potential advantages in manufacturing complexity, and cost of goods compared with alternative approaches.

Clinical data across two trials in patients with advanced solid tumors have demonstrated vaccinespecific immune responses in 88–100% of patients, including de novo T-cell responses in 85% of patients. These responses remained durable for more than one year after the final dose, supporting the potential of Nykode’s platform to generate strong and sustained immune responses.

Summit Program and Presentation Details

1. Workshop: Streamlining Manufacturing, Analytics & Supply Chain Operations to Accelerate
Delivery of Personalized Cancer Vaccines
Speaker: Michael Engsig
Date: Tuesday, December 1, 2026
Time: 9:00 a.m.

2. Seminar: From Promise to Practice: Enabling the Next Generation of Personalized Cancer
Vaccines
Speaker: Agnete Fredriksen
Date: Thursday, December 3, 2026
Time: 9:00 a.m

3. Panel Discussion: Comparing Personalized vs. Off-the-Shelf Cancer Vaccines to Choose
the Right Strategy for the Right Indication
Panelist: Agnete Fredriksen
Date: Thursday, December 3, 2026
Time: 11:30 a.m.

(Press release, Nykode Therapeutics, NOV 19, 2026, View Source [SID1234675038])

Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers

On November 19, 2026 AstraZeneca reported that Biologics License Application (BLA) for sonesitatug vedotin (Sone-Ve) has been accepted and granted Priority Review in the US for the 2nd and later-line treatment of patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or oesophageal adenocarcinoma (EAC) with Claudin 18.2 (CLDN18.2) expression on at least 25% of tumour cells at any staining intensity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available treatment options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance.1 The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the second quarter of 2027.

CLDN18.2 has emerged as an important therapeutic target for these patients, with an estimated 60% of gastric/GEJ cancers expressing CLDN18.2 in 25% or more of tumour cells.2 Each year, there are roughly 7,500 patients in the US treated in the 2nd and later-line setting for advanced or metastatic CLDN18.2-positive, non-HER2-positive gastric/GEJ cancers.3 The majority of patients with gastric/GEJ cancers are diagnosed at an advanced or metastatic stage, where the prognosis is especially poor and treatment options are limited.4 Less than 20% of patients diagnosed at this late-stage survive more than one year.5

Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: "After progressing on first-line treatment, patients with Claudin 18.2-positive advanced gastric cancer have no targeted options. Sone-Ve is the first ADC targeting Claudin 18.2 to improve overall survival for patients compared to current standard of care in this setting and across a population that encompasses a much broader definition of Claudin 18.2 positivity than for current drugs. This Priority Review of our submission speaks to the significant potential of this medicine and accelerates the ability to bring forward a new targeted approach and alternative to traditional chemotherapy for thousands of patients in the US."

The BLA is based on results from the CLARITY-Gastric01 Phase III trial which were presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper).

In the trial, Sone-Ve reduced the risk of death by 42% compared to investigator’s choice of therapy (based on an OS hazard ratio [HR] of 0.58; 95% confidence interval [CI] 0.47–0.73; p=0.000004) in the 2nd- and later line setting. Median OS was 10.6 months for patients treated with Sone-Ve compared to 6.4 months for investigator’s choice of therapy. The OS benefit observed was consistent across most predefined subgroups, including subgroups based on lower or higher CLDN18.2 expression levels.6

The tolerability profile of Sone-Ve was manageable and consistent with its known safety profile with no new safety signals identified. Fewer Grade 3 or higher treatment-related adverse events.6

Sone-Ve has received Orphan Drug Designation from the US Food and Drug Administration and the European Commission for the treatment of gastric and GEJ cancers. It has also received Breakthrough Designation in China for the 2nd-line treatment of gastric cancer. Regulatory applications are currently under review in the EU, China and several other countries based on the CLARITY-Gastric01 results.

Notes

Gastric and GEJ cancers
Gastric (stomach) cancer is the fifth most common cancer worldwide and the fifth-leading cause of cancer-related death.7 Nearly one million new patients were diagnosed with gastric cancer in 2024, with approximately 650,000 deaths reported globally. In many regions, its incidence has been increasing in patients younger than 50 years old, along with other gastrointestinal (GI) malignancies.7

GEJ cancer is a type of gastric cancer that arises from and spans the area where the oesophagus connects to the stomach.8

Most advanced gastric cancer patients will eventually experience disease progression after standard 1st-line therapies, and subsequent lines yield poor outcomes, with median survival of 5-10 months for patients receiving 2nd and later-line systemic treatments.9-11

Each year, there are roughly 183,500 patients in the US, EU, China and Japan treated in the 2nd and later-line setting for advanced or metastatic CLDN18.2-positive, non-HER2-positive gastric/GEJ cancers.3

CLARITY-Gastric01
CLARITY-Gastric01 is a randomised, open-label, sponsor-blinded, multicentre, global Phase III trial evaluating Sone-Ve as a 2nd and later-line therapy for patients with advanced or metastatic gastric cancer, GEJ cancer or EAC with CLDN18.2 expression in 25% or more of tumour cells, with IHC+ of any intensity. In the trial, patients were randomised 1:1:1 in Stage 1 (dose selection) to Sone-Ve monotherapy 2.2mg/kg or 1.8mg/kg every three weeks, or investigator’s choice of therapy (including regionally accepted chemotherapies or targeted therapies), the comparator arm. In Stage 2, the trial continued with Sone-Ve 2.2mg/kg as the recommended Phase III dose.

The efficacy analyses from this study will also provide the basis to evaluate the clinical performance of the Ventana SP455 assay for the identification of patients with advanced or metastatic gastric, GEJ or EAC cancers expressing CLDN18.2 who may benefit from Sone-Ve.

The trial is being conducted in 175 centres across 19 countries, including in North America, Europe, South America and Asia. Its dual primary endpoints are progression-free survival as assessed by blinded independent central review in the 2nd and later-line setting and OS in the 3rd and later-line setting. A key secondary endpoint is OS in the 2nd and later-line setting.

Sonesitatug Vedotin (Sone-Ve)
Sone-Ve is a novel investigational antibody drug conjugate (ADC) targeting CLDN18.2, a protein found in the stomach lining and a validated therapeutic target in oncology, particularly for GI cancers. Sone-Ve consists of an anti-CLDN18.2 monoclonal antibody, a protease-degradable linker and a cytotoxic small molecule MMAE payload.

AstraZeneca entered into a global exclusive licence agreement with KYM Biosciences to develop and commercialise Sone-Ve in March 2023. The Company recently announced a clinical collaboration agreement with Summit Therapeutics to evaluate Sone-Ve in combination with ivonescimab, a first-in-class PD-1/VEGF bispecific, in GI cancers.

In addition to CLARITY-Gastric01, Sone-Ve is being evaluated in the CLARITY-Gastric02 Phase III trial in combination with capecitabine, with or without rilvegostomig, as a 1st-line treatment for advanced or metastatic gastric cancer, GEJ cancer and EAC. In Phase II development, Sone-Ve is being evaluated in patients with advanced solid tumours in multiple combinations across settings, including in CLDN18.2-positive pancreatic and biliary tract cancer (BTC).

(Press release, AstraZeneca, NOV 19, 2026, View Source [SID1234674999])

DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors

On November 19, 2026 DISCO Pharmaceuticals ("DISCO") reported a strategic collaboration and option-to-license agreement with AbbVie to discover and develop novel AND-gated bispecific therapeutics for solid tumors with high unmet medical need.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, DISCO will receive $40 million in upfront payments and is eligible for up to $2.5 billion in option, development, and other milestone payments, plus tiered royalties on worldwide net sales.

"The collaboration with AbbVie represents an important opportunity to deliver the next generation of precision medicines to patients with difficult-to-treat solid tumors," said Mark Manfredi, Ph.D., CEO of DISCO Pharmaceuticals. "Our AND-gated approach is designed to selectively target tumor cells while sparing healthy tissue, thus offering a potentially differentiated path in precision oncology. Our DISCOtech platform’s unique ability to identify tumor-selective target pairs provides the foundation for therapies with the potential for a wider therapeutic window."

"We look forward to working together with AbbVie towards the shared goal of creating transformative therapeutics for patients. This collaboration further underscores the potential of our differentiated platform and complements our portfolio of internal and partnered pipeline programs," added Ajla Hrle, Ph.D., CBO of DISCO Pharmaceuticals.

(Press release, DISCO Pharmaceuticals, NOV 19, 2026, View Source [SID1234675023])

Biohaven’s Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026

On November 19, 2026 Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, reported clinical data from the ongoing Phase 1 study of BHV-1530, its first in class potential FGFR3-directed antibody-drug conjugate (ADC) with a novel topoisomerase I (TopoIx) payload. The data were presented today by Gerald S. Falchook, M.D., Director of Sarah Cannon Research Institute at HCA HealthONE, in an oral presentation during Plenary Session 3 at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain. As of the October 19, 2026 data cutoff, 30 patients had received BHV-1530 monotherapy every three weeks (Q3W) at doses from 1.0 to 12.0 mg/kg, and dose escalation is ongoing. Patients had received a median of two prior lines of therapy for advanced disease, and all patients with UC had progressed on EV+P.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Among 10 efficacy-evaluable patients with activating FGFR3 alterations, treated with BHV-1530 at doses of 3.3 mg/kg or higher, 9/10 had a tumor reduction and 6 achieved a partial response (PR; confirmed or unconfirmed, by investigator assessment per RECIST v1.1; Figure 1). Responses were observed in tumors with FGFR3 mutations and fusions, including in 3 of 5 patients with UC and all 3 patients with HPV-positive HNSCC. All responders remained on treatment as of the data cutoff, some for more than 6 months.

Gerald S. Falchook, M.D. commented, "Many patients in this study had progressed on multiple prior therapies, including enfortumab vedotin plus pembrolizumab and FGFR inhibitors in urothelial cancer, so seeing durable responses is very encouraging." Dr. Falchook added, "We also saw deep responses in HPV-positive head and neck cancer, where options after immunotherapy are limited. Importantly, BHV-1530 has been well tolerated, with no dose-limiting toxicities and none of the hyperphosphatemia, nail or retinal toxicities that often restrict FGFR tyrosine kinase inhibitor therapy."

In UC, where all patients had progressed on prior EV+P, partial responses occurred in 3 of 5 patients with FGFR3-altered tumors, including a patient who had also received a prior FGFR inhibitor. Tumor reductions were also observed in the 2 patients with FGFR3 wild-type tumors, including one partial response pending confirmation.

Dr. Falchook presented the clinical case of a patient with HPV-positive metastatic HNSCC and an FGFR3 S249C mutation, who had received four prior lines of therapy including chemoradiation, a platinum doublet and immunotherapy. This patient achieved a confirmed partial response, with a 67% reduction in target lesions at Week 6 that deepened to 86% by Week 24, (Figure 3) and remains on therapy beyond 6 months with no treatment-related adverse events. This case illustrates the speed and depth of response in a highly refractory patient who failed prior standard of care.

BHV-1530 was well tolerated across all dose levels in 30 patients, with no dose-limiting toxicities, treatment-related serious adverse events or treatment-related deaths. The most common adverse events, nausea (43%) and fatigue (37%), were all Grade 1 or 2. Hematological toxicity was mostly low grade and manageable. None of the toxicities that commonly limit FGFR inhibitor therapy (hyperphosphatemia, nail dystrophy or central serous retinopathy) were observed, and no interstitial lung disease (ILD) was reported. Pharmacokinetic data showed that BHV-1530 is highly stable in circulation, with free payload exposure below 1% of ADC exposure, and a half-life of 7 to 14 days that supports Q3W dosing.

Nushmia Khokhar, M.D., Chief Medical Officer of Oncology at Biohaven stated, "Unlike FGFR tyrosine kinase inhibitors, which block kinase signaling inside the cell, BHV-1530 is an ADC designed to bind FGFR3 on the tumor cell surface, be internalized and release a potent topoisomerase I payload, independent of kinase-domain resistance mutations."

Dr. Khokhar added, "Following a recent Type C meeting with the FDA, we are excited to advance BHV-1530 into a pivotal study in FGFR3-altered tumors, beginning with urothelial cancer, as early as the first half of 2027, with the goal of supporting a potential accelerated approval."

FGFR3 is frequently altered or overexpressed in UC. Activating mutations or fusions, together with overexpression of the wild-type receptor, are found in about half of metastatic UC and in 70% to 80% of non-muscle-invasive bladder cancer, and are also seen in head and neck, lung and other solid tumors (Figure 4). Enfortumab vedotin plus pembrolizumab is now the first-line standard of care for advanced UC, but many patients eventually progress and options after progression remain limited. The only FDA-approved FGFR-targeted therapy for advanced UC is an oral pan-FGFR tyrosine kinase inhibitor (TKI), indicated only for previously treated patients whose tumors carry a susceptible FGFR3 alteration, which leaves patients whose tumors overexpress wild-type FGFR3 without a targeted option. Pan-FGFR TKIs also inhibit FGFR1, FGFR2 and FGFR4, and their labeled class effects include hyperphosphatemia, nail disorders, stomatitis and retinopathy, which often require dose interruptions or reductions. Resistance can also emerge through mutations in the kinase domain where these drugs bind. BHV-1530 is designed to bind FGFR3 on the tumor cell surface rather than inhibit its kinase, and is being studied in patients with and without FGFR3 alterations.

BHV-1530 takes a different approach to FGFR3 than approved pan-FGFR tyrosine kinase inhibitors, which block kinase signaling across the FGFR family (Figure 5). The investigational antibody-drug conjugate is designed to bind selectively to FGFR3 on the tumor cell surface and deliver its TopoIx payload inside the cell, with no detectable binding to FGFR1, FGFR2 or FGFR4 in preclinical studies.

About Study BHV1530-101

BHV1530-101 (NCT06874335) is a Phase 1, first-in-human, multicenter study of BHV-1530 as monotherapy and in combination with an anti-PD-1 antibody in adults with advanced solid tumors. Patients with UC, HNSCC or non-small cell lung cancer (NSCLC) were enrolled irrespective of FGFR3 alteration status, without a minimum FGFR3 expression threshold. Patients with other solid tumors were eligible if their tumors harbored an activating FGFR3 alteration.

About BHV-1530

BHV-1530 is an antibody-drug conjugate directed against FGFR3, a validated but underexploited target in urothelial cancer and other FGFR3-driven cancers and is a first-in-class potential FGFR3-directed ADC incorporating Biohaven’s proprietary TopoIx payload. Unlike approved FGFR tyrosine kinase inhibitors, which are restricted to genomically selected patients and constrained by class-related toxicities, BHV-1530 is designed to target FGFR3 with the potential to address both FGFR3-altered and wild-type overexpressing tumors. BHV-1530 is being studied in an ongoing Phase 1 dose-escalation trial in unselected patients with advanced urothelial cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer who have failed standard-of-care therapy, as well as other tumor types harboring FGFR3 genomic alterations. Biohaven has initiated combination cohorts evaluating BHV-1530 with anti-PD-1 therapy, including the combination with LIBTAYO (cemiplimab) which is now enrolling.

(Press release, Biohaven Pharmaceutical, NOV 19, 2026, View Source [SID1234675000])

Scancell Provides Corporate and Clinical Update

On November 19, 2026 Scancell Holdings plc (AIM: SCLP), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumour immune responses in difficult-to-treat cancers, reported an update on progress across its clinical and preclinical pipeline, including the grant of Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for inzitagene plasmivec and new data from the Phase 2 ModiFY trial of Modi-1.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Phillip L’Huillier, Chief Executive Officer, Scancell, commented: "We are very encouraged by the progress across our pipeline. The new data from the ongoing ModiFY trial, demonstrate that Modi-1 can induce vaccine-specific immune responses in a subset of patients with renal cell carcinoma (RCC), with these responses being associated with longer progression-free survival. These findings provide encouraging evidence of clinical activity of our Moditope platform and support further evaluation of Modi-1. Our next steps will focus on better understanding these immune responses, exploring potential biomarkers and using these insights to inform future clinical development.

The FDA’s grant of RMAT designation for iSCIB1+, alongside Fast Track, recognises its potential to address an unmet need in advanced melanoma and gives us closer engagement with the Agency as we start Phase 3. With iSCIB1+ approaching a major clinical milestone and our plans for a Nasdaq listing progressing, we remain committed to advancing our lead program while unlocking the potential of our broader immunotherapy pipeline."

DNA ImmunoBody

inzitagene plasmivec (iSCIB1+) in advanced melanoma
inzitagene plasmivec in combination with checkpoint inhibitors continues to show durable positive benefit to patients in the Phase 2 SCOPE trial. The latest data cut, analysed November 12th, shows overall survival is sustained at 24 months at 82% for SCIB1 and iSCIB1+ (n=80) cohorts. iSCIB1+ remains superior (to SCIB1) at 24 months at 87%.
Progression-free survival (PFS) rate for combined SCIB1 and iSCIB1+ (n=80) at 24 months is 65% in the HLA-target population. For iSCIB1+ at 24 months PFS is 71% due to one patient showing progression. Standard of Care, ipi/nivo at 24mths was 41.5% (checkmate 067 Study)
The rate of complete responders has improved to 28% for SCIB1 and iSCIB1+ (n=80) cohorts (31% for iSCIB1+ Cohort 3).
The global Phase 3 trial of iSCIB1+ remains on track for first-patient-in (FPI) in December 2026, following U.S Food and Drug Administration (FDA) IND clearance and Clinical Trial Authorisation from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) earlier this year. iSCIB1+ has also been granted a Fast Track Designation from the FDA.
The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) for the allowing benefits of Fast Track and Breakthrough Therapy designations, intensive FDA guidance on efficient drug development and eligibility for rolling review, priority review and accelerated approval if relevant criteria are met. Scancell will request an initial comprehensive multidisciplinary RMAT meeting with the FDA to discuss the development program, including the Phase 3 trial and manufacturing strategy for the Phase 3 trial.
The World Health Organization (WHO) has granted "inzitagene plasmivec" as the International Nonproprietary Name (INN) for iSCIB1+. An INN is the single, globally recognised non-proprietary name used by regulators, prescribers and scientific publications.
More mature PFS data and interim overall survival (OS) data from SCOPE expected in H1 2027.
Research has begun on new ImmunoBody candidates targeting tumour-associated antigens including KRAS, cMET and FAP, building on the platform validation provided by iSCIB1+. Potential indications include pancreatic ductal adenocarcinoma ("PDAC"), non-small cell lung cancer ("NSCLC") and microsatellite stable colorectal cancer ("MSS CRC").

Moditope ModiFY Trial

The Phase 2 ModiFY trial of Modi-1 with checkpoint inhibitors (CPIs) in renal cell carcinoma (RCC) and head and neck squamous cell carcinoma (HNSCC) is fully recruited in both cohorts. The objective of the study was to assess dosing schedule, formulation, immunogenicity and tumour type.

Full RCC cohort (n=43, Modi-1 plus ipilimumab and nivolumab): objective response rate (ORR) 48%; median PFS 7.8 months.

46% of RCC patients mounted a vaccine-specific immune response to Modi-1’s citrullinated peptides; these responders outperformed non-responders:

6-month PFS: 75% vs 50% (p=0.0025)
ORR: 58% vs 36%
Median PFS: not reached at 22 months’ follow-up vs 6 months in non-responding patients

Safety: no toxicity beyond that expected with ipilimumab and nivolumab, and no evidence of autoimmune disease.

59% of RCC responders received Modi-1ekv, the new soluble, stable formulation, on an accelerated schedule, achieving a 6-month PFS rate of 90% and supporting its further evaluation.

In HNSCC, immune responders had median PFS of 4.5 vs 2 months for non-responders. Not statistically significant, but further exploratory evidence linking immune response to outcome.

SCOPE (advanced melanoma) and ModiFY (RCC) results are informing future clinical development. With Modi-1 target antigens broadly expressed across tumour types, options include the neoadjuvant and adjuvant settings, where disease control is likely to be longer, and metastatic indolent tumours.

RNA-seq of immune responders is under way to understand the mechanism and identify a predictive biomarker. Immune receptors isolated from clinical responders could also open new therapeutic approaches, potentially in faster-progressing tumours.

GlyMab Antibodies

Based on a recent update from Genmab, Scancell are confident that the partnered SC129 and SC2811 candidates are being progressed towards clinical development, with potential further near-term milestone payments, dependent on Genmab’s progress and decisions.

SC134-TCAB, the lead wholly owned GlyMab candidate, is in developability studies as Scancell evaluates its potential progression towards clinical development.

Further GlyMab candidates are SC27 (targeting Lewis Y) and GT200 (targeting SLAN). Initial preclinical data suggest SC27 could be investigated as a T-cell engager (TCE) or antibody drug candidate in various indications, and GT200 in ovarian cancer.

Corporate update

Company remains on track to complete its NASDAQ listing late 2026/early 2027.

Completion of the transaction will allow financing for the execution of the Phase 3 global registrational trial of inzitagene plasmivec in advanced melanoma, to be initiated in December 2026.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

About inzitagene plasmivec

inzitagene plasmivec is a DNA ImmunoBody in development for the treatment of melanoma. Administered by needle-free intramuscular injection, inzitagene plasmivec encodes an antibody targeting the melanoma-associated antigens gp100 and TRP-2, priming high-avidity T cells to generate a robust and durable anti-tumor response. In the Phase 2 SCOPE trial in first-line advanced melanoma, inzitagene plasmivec in combination with ipilimumab and nivolumab demonstrated a PFS of 77% at 22 months in the target HLA population, with no increase in checkpoint inhibitor-related toxicities. inzitagene plasmivec has demonstrated a favorable safety profile and clinically meaningful activity as a monotherapy in Phase 1 and in combination with checkpoint inhibitors in the Phase 2 SCOPE trial in advanced melanoma.

inzitagene plasmivec has been granted Fast Track Designation for the treatment of advanced melanoma from the FDA. The registrational Phase 3 trial of inzitagene plasmivec in patients with advanced melanoma has received an IND clearance from the FDA and CTA from the UK MHRA and is expected to begin in the second half of 2026. A Phase 2 trial of iSCIB1+ in patients with neo/adjuvant melanoma is planned for the first half of 2027.

inzitagene plasmivec is an investigational medicinal product. It has not been approved by the MHRA, the FDA or any other regulatory authority for the treatment of melanoma or any other indication,
and its safety and efficacy have not been established.

Scancell (LSE:SCLP; www.scancell.co.uk) is a late-stage clinical biotechnology company developing targeted, off-the-shelf, active immunotherapies, generated by the ImmunoBody and Moditope platforms, designed to stimulate durable anti-tumor responses. The lead product, inzitagene plasmivec, is a DNA ImmunoBody that has demonstrated a favorable safety profile and clinically meaningful activity both as a monotherapy, in a Phase 1 trial, and in combination with checkpoint therapies in a Phase 2 trial in patients with melanoma. Modi-1 is a Moditope peptide currently being evaluated in a Phase 2 study in head & neck and renal cancers. In addition, Scancell is advancing a pipeline of high affinity GlyMab antibodies targeting tumor specific glycans, two of which have been licensed for further development to Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.

Additional Information

In connection with the proposed business combination (Business Combination) between Neuphoria Therapeutics Inc. (Neuphoria) and Scancell, Scancell and Neuphoria filed with the U.S. Securities and Exchange Commission (SEC) a Registration Statement on Form F-4 (Registration Statement) on October 9, 2026, containing a preliminary proxy statement of Neuphoria and a preliminary prospectus of Scancell. After the Registration Statement is declared effective, Neuphoria will mail a definitive proxy statement/prospectus related to the proposed Business Combination to its stockholders. This communication does not contain all the information that should be considered concerning the proposed Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the proposed Business Combination. Neuphoria’s stockholders and other interested persons are advised to read the preliminary proxy statement/prospectus contained in the Registration Statement, any amendments thereto and, when available, the definitive proxy statement/prospectus and other documents filed in connection with the proposed Business Combination, as these materials contain or will contain important information about Scancell, Neuphoria and the proposed Business Combination. When available, the definitive proxy statement/prospectus and other relevant materials for the proposed Business Combination will be mailed to stockholders of Neuphoria as of a record date to be established for voting on the proposed Business Combination. Stockholders of Neuphoria can obtain copies of the Registration Statement and the preliminary proxy statement/prospectus and, when available, the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, at the SEC’s website at www.sec.gov, or by directing a written request to: Neuphoria Therapeutics Inc, 100 Summit Dr, Burlington, Massachusetts 01803.

Participants in the Solicitation

Neuphoria and its directors and executive officers may be deemed participants in the solicitation of proxies from Neuphoria’s stockholders with respect to the Business Combination. A list of the names of those directors and executive officers and a description of their interests in Neuphoria is contained in Neuphoria’s proxy statement on Schedule 14A for the 2025 Annual Meeting, which was filed with the SEC on November 24, 2025 and is available free of charge at the SEC’s web site at www.sec.gov, or by directing a written request to Neuphoria Therapeutics Inc, 100 Summit Dr, Burlington, Massachusetts 01803. For additional information regarding the interests of such participants in the proposed Business Combination, stockholders should read the preliminary proxy statement/prospectus contained in the Registration Statement filed by Scancell with the SEC on October 9, 2026, any amendments thereto and, when available, the definitive proxy statement/prospectus.

Scancell and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Neuphoria in connection with the proposed Business Combination. For the names of such directors and executive officers and information regarding their interests in the proposed Business Combination, stockholders should read the preliminary proxy statement/prospectus contained in the Registration Statement filed by Scancell with the SEC on October 9, 2026, any amendments thereto and, when available, the definitive proxy statement/prospectus.

(Press release, Scancell, NOV 19, 2026, View Source [SID1234675024])